ClinicalTrials.gg
RecruitingNCT07478510DNA_ARFIDUpdated Apr 16, 2026

Cognitive Evaluation of Patients With Eating Disorders

An observational study in ARFID, Anorexia Nervosa and Bulimia Nervosa, sponsored by Istituti Clinici Scientifici Maugeri SpA. Recruiting at 3 sites in Italy. Open to participants aged 14 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-16.

Sponsored by Istituti Clinici Scientifici Maugeri SpA · Observational

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
84
Ages
14 Years to 65 Years
Sex
All
01

Study summary

The goal of this cross - sectional observational study is to improve understanding of the psychological and cognitive characteristics of Feeding and Eating Disorders (FEDs), a group of conditions that represent a growing public health concern due to their significant impact on physical health, emotional well-being, and everyday functioning. Within this broader diagnostic category, particular attention is given to Avoidant/Restrictive Food Intake Disorder (ARFID), a diagnosis introduced in the DSM-5 and still relatively underexplored compared to other feeding and eating disorders.

Despite its clinical relevance, ARFID remains less well understood in terms of its underlying cognitive and psychological mechanisms. Individuals with ARFID often experience severe food avoidance or restriction that is not driven by weight or shape concerns, but rather by sensory sensitivities, fear of negative consequences of eating, or a lack of interest in food. For this reason, investigating ARFID can offer important insights into the diversity of mechanisms involved in feeding and eating disorders as a whole.

The study has two main objectives. The first objective is to examine the cognitive profile of individuals with ARFID, with a specific focus on autistic traits and cognitive flexibility, as previous research suggests potential overlaps between ARFID and neurodevelopmental conditions such as Autism Spectrum Disorders. Cognitive flexibility refers to the ability to adapt thoughts and behaviors in response to changing situations, and reduced flexibility may contribute to rigid eating patterns and food avoidance.

The second objective is to explore the role of body representation (how individuals perceive and mentally represent their own body) and inhibitory control (the ability to regulate or suppress automatic responses) in shaping the cognitive and behavioral features of ARFID and other feeding and eating disorders. These processes may help distinguish ARFID from other diagnoses and clarify shared and disorder-specific mechanisms across the FED spectrum.

The study involves adult participants of all genders, including individuals diagnosed with ARFID, anorexia nervosa, and bulimia nervosa, as well as healthy control participants without a history of feeding or eating disorders. This design allows meaningful comparisons between different diagnostic groups and with the general population.

The main questions the study aims to answer are:

Do individuals with ARFID show a distinct cognitive profile, particularly in terms of autistic traits and cognitive flexibility, compared to individuals with other feeding and eating disorders and healthy controls?

How do body representation and inhibitory control contribute to differences in eating-related behaviors across feeding and eating disorders?

Are there differences in brain activity associated with implicit, automatic attitudes toward food in individuals with feeding and eating disorders compared to healthy individuals?

Where comparison groups are included, researchers will compare participants with ARFID, anorexia nervosa, bulimia nervosa, and healthy controls to examine differences in cognitive functioning, psychological characteristics, and neural responses related to food processing.

Participants will be asked to take part in a series of non-invasive and well-established research activities, designed to be accessible and safe. These include:

Completing self-report questionnaires assessing autistic traits, body image perception, and general psychological well-being;

Performing computer-based tasks that assess cognitive flexibility and decision-making;

Completing behavioral tasks designed to measure inhibitory control and automatic associations with food-related stimuli;

02

Conditions studied

  • ARFID
  • Anorexia Nervosa
  • Bulimia Nervosa
  • Cognitive Flexibility
  • Implicit Association Test
  • Executive Functions
03

In context

Avoidant Restrictive Food Intake Disorder

41 studies on the registry are indexed under Avoidant Restrictive Food Intake Disorder; 12 are open to participants now.

This study's planned enrollment of 84 is below the median of 110 across 13 observational studies indexed under Avoidant Restrictive Food Intake Disorder.

Browse Avoidant Restrictive Food Intake Disorder studies →

Lead sponsor

Istituti Clinici Scientifici Maugeri SpA is the lead sponsor of 128 studies on the registry; 52 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
14 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population includes adolescent and adult participants aged between 14 and 65 years, of both sexes, recruited among individuals diagnosed with Feeding and Eating Disorders and healthy control volunteers. The clinical group consists of patients with a diagnosis of Avoidant/Restrictive Food Intake Disorder, anorexia nervosa, or bulimia nervosa, with a Body Mass Index (BMI) lower than 25.

Eligible participants must meet the diagnostic criteria for a Feeding and Eating Disorder according to DSM-5-TR and must provide written informed consent to participate in the study. For participants under the age of 18, written consent from parents or legal guardians is required in addition to the minor's assent.

A group of healthy control participants will be recruited in order to obtain a sample balanced with the patient group in terms of sex, age, and educational level. The same inclusion and exclusion criteria applied to the patient group will be considered for the control group.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of a Feeding and Eating Disorder (ARFID, anorexia nervosa, or bulimia nervosa);
  • Patients of both sexes;
  • Age between 14 and 65 years;
  • Confirmed diagnosis of a Feeding and Eating Disorder;
  • (BMI) \< 25;
  • Signed form for participation in the study.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of Bipolar Disorder according to criteria;
  • Diagnosis of a Schizophrenia Spectrum Disorder according to DSM-5-TR criteria;
  • Intellectual disability according to DSM-5-TR criteria;
  • Presence of brain tumors;
  • History of seizure events;
  • Presence of other moderate to severe neurological disorders;
  • Lack of the patient's consent to voluntary participation in the study;
  • Lack of parental or legal guardian consent for participation of a minor in the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Observational model
Other
Time perspective
Other
Enrollment
84 participants (estimated)
Patient registry
No

Groups and cohorts

  • Healthy control

    Every participant recieve all the interventions described, each one of them with the specific randomization of subministration.

    Behavioral: Go/No-go · Behavioral: IAT · Behavioral: WCST

  • ARFID

    Patients with Avoidant Restrictive Food Intake Disorder. Every participant recieve all the interventions described, each one of them with the specific randomization of subministration.

    Behavioral: Go/No-go · Behavioral: IAT · Behavioral: WCST

  • AN/BN

    Patients with a diagnosis of Anorexia Nervosa or Bulimia Nervosa. Every participant recieve all the interventions described, each one of them with the specific randomization of subministration.

    Behavioral: Go/No-go · Behavioral: IAT · Behavioral: WCST

Interventions

  • BehavioralGo/No-go

    The investigators designed a specific task, base in literature, to evaluate the inibithory response to food stimuli of different types (high calories, low calories, neutral stimuli). The images have been defined by a pilot selection and added to the task designed on Psychopy.

  • BehavioralIAT

    The investigators designed a specific task, base in literature, to evaluate the implicit association of body images (overweight, underweight, normalweight) and word to different lables. The body images have been defined by a pilot selection and added to the task designed on Psychopy.

  • BehavioralWCST

    The Wisconsin Card Sorting Test (WCST) is a neuropsychological assessment of executive function, cognitive flexibility, and abstract reasoning. Participants match stimulus cards based on color, form, or number, adapting to changing, unstated rules based on examiner feedback. It measures the ability to display flexibility in the face of changing schedules of reinforcement, specifically "set-shifting". A participant is given a deck of cards and told to match them, but not how. The examiner says "right" or "wrong," forcing the participant to deduce the rule (color, shape, or number). The rule changes unexpectedly after a certain number of correct matches. It provides scores for categories completed, trials, total errors, and, critically, perseverative errors (continuing to use a previous, invalid rule). The investigators used the 128 cards version.

06

What researchers measure

Primary outcomes

  1. What is the cognitive profile of patients with ARFID, with particular reference to autistic traits and cognitive flexibility?

    The Autism Spectrum Quotient (AQ) questionnarie has the purpose to evaluate the levels of autistic traits in each participant and permit to understand the differences between the groups. The scoring of this questionnaire stays in the range 0-50, where 0 is the minimum and associated with less autistic traits and 50 is the maximum outcome possible, explaining elevated autistic traits. Usually, the cut-off is defined as 32, over that score is possible to define the presence of autistic traits.

    Time frame: Baseline

  2. What is the cognitive profile of patients with ARFID, with particular reference to autistic traits and cognitive flexibility?

    The higher the percentage of perseverative errors out of the total errors made on the Wisconsin Card Sorting Test (WCST), the lower the subject's cognitive flexibility. The WCST assesses executive functions, particularly cognitive flexibility, set-shifting ability, and problem-solving strategies. Scoring is typically based on several indices, including number of categories completed, total errors, and perseverative errors, with perseverative errors often expressed as a percentage of total responses. There is no universally accepted clinical cut-off for WCST performance, as interpretation is usually based on comparison with age-adjusted normative data; however, higher percentages of perseverative errors are generally interpreted as indicating greater executive dysfunction. The scale starts at 0%, which indicates full cognitive flexibility, and increases accordingly torwards 100%, indicating cognitive rigidity.

    Time frame: Baseline

Secondary outcomes

  1. What is the role of body representation and inhibitory control capacity in the differential diagnosis between ARFID and other eating disorders, such as Anorexia Nervosa and Bulimia Nervosa?

    The assessment of body representation is carried out through the scoring and comparison of participants' scores through the scoring of the Implicit Association Task (IAT), involving implicit associations with body images. Scores on the D-scores emerging as outcomes from the computerized IAT task will be evaluated. The interpretation of scoring has this pattern: 1. +0.15 \<: no implicit preference 2. 0.16 - 0.35: weak preference 3. 0.36 - 0.65: moderate preference 4. \> 0.65: strong preference The theoretical range of D score is between -2 and 2, but in empirical practise it's moreover between -1,5 and 1,5.

    Time frame: Baseline

  2. What is the role of body representation and inhibitory control capacity in the differential diagnosis between ARFID and other eating disorders, such as Anorexia Nervosa and Bulimia Nervosa?

    The assessment of body representation is carried out through the scoring and comparison of participants' scores on one of the questionnaires included in the project, namely the Body Image Concern Inventory (BICI). It is a 19-item self-report questionnaire assessing dysmorphic concerns related to body image. Each item is rated on a 5-point Likert scale (1 = never, 5 = always). The total score is obtained by summing all items and ranges from 19 to 95, with higher scores indicating greater body image concern. A commonly used cut-off is ≥55 (95th percentile in normative samples), suggesting clinically relevant dysmorphic concern. The scale also includes two subscales: F1 - Dysmorphic Symptoms (preoccupation with perceived appearance flaws) and F2 - Symptom Interference (impact of these concerns on daily functioning).

    Time frame: Baseline

  3. What is the role of body representation and inhibitory control capacity in the differential diagnosis between ARFID and other eating disorders, such as Anorexia Nervosa and Bulimia Nervosa?

    The evaluation of inhibitory control capacity is carried out through a Go/No-go task. The test consists of high and low calorie food pictures or neutral stimuli (circles and squares). This kind of task presents two main outcomes: reaction time (RT) and accuracy. Reaction time is recorded in milliseconds (ms) and has no theoretical maximum, but in this specific protocol the range of evaluations of answers is between 300 and 1000 ms, where stimuli under 300ms reflects a pattern of impulsivity and stimuli over 1000 ms of answers are not registred by the task, defining low reactivity. Accuracy represents the percentage of correct responses (0-100%). The task does not have validated clinical cut-offs, as it is a continuous experimental measure rather than a diagnostic test. Normative interpretation is usually based on sample comparison or statistical ranges (e.g., mean ± 2 SD) rather than fixed thresholds.

    Time frame: Baseline

  4. What is the role of body representation and inhibitory control capacity in the differential diagnosis between ARFID and other eating disorders, such as Anorexia Nervosa and Bulimia Nervosa?

    The Eating Disorder Inventory-3 (EDI-3) is a self-report questionnaire used to assess psychological and behavioral traits associated with eating disorders and is commonly used in the differential diagnosis, particularly to evaluate body image disturbance. It includes 91 items rated on a 6-point Likert scale that are recoded from 0 to 4 and summed to produce 12 primary scales. The instrument does not provide a single total score and cut-offs are not strictly diagnostic, although T-scores ≥60-65 are generally considered clinically elevated and ≥70 indicates high clinical concern. Scales most relevant for research on body representation and differential diagnosis are Drive for Thinness, Body Dissatisfaction, and Bulimia, which form the Eating Disorder Risk Composite. Individuals with ARFID are expected to show low scores on these body-image related dimensions compared to those with Anorexia Nervosa or Bulimia Nervosa.

    Time frame: Baseline

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2024 (actual). Primary completion is estimated for Mar 2028, 40 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2026
First posted
Mar 17, 2026
StartActual
Nov 26, 2024
Primary completionEst.
Mar 31, 2028
CompletionEst.
Mar 31, 2028
Last update
Apr 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07478510
Collaborators
Istituto Psicologico Italiano s.r.l.s., ASST Fatebenefratelli Sacco
Responsible party
Sponsor
First posted
Mar 17, 2026
Start date
Nov 26, 2024
Primary completion
Mar 31, 2028 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Apr 16, 2026

Study contacts

Giulia Mattavelli, Associated prof., researcher
Contact
giulia.mattavelli@iusspavia.it
+39 3397893500

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion